戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 e matter < 2.5u (PM(2.5)) has been linked to cardiopulmonary disease.
2 ary arterial hypertension is a severe lethal cardiopulmonary disease.
3 group A) or absence (group B) of preexisting cardiopulmonary disease.
4  Healthy volunteers were screened to exclude cardiopulmonary disease.
5 ong susceptible individuals with preexisting cardiopulmonary disease.
6 10% of cirrhosis patients, in the absence of cardiopulmonary disease.
7 y explaining distinct responses of the RV to cardiopulmonary disease.
8 ere aged 37, 46, and 55 yrs and had no prior cardiopulmonary disease.
9 mulations in persons > or =65 years old with cardiopulmonary disease.
10 ized as an important pathogen in adults with cardiopulmonary disease.
11 significant changes in patients with chronic cardiopulmonary disease.
12 h, or a history of venous thromboembolism or cardiopulmonary disease.
13 ic and prognostic value in the evaluation of cardiopulmonary disease.
14 hypertension (PAH) is an uncommon and deadly cardiopulmonary disease.
15  illness (ARI) and triggers exacerbations of cardiopulmonary disease.
16 ipants without smoking, obesity, or clinical cardiopulmonary disease.
17 te lung function assessment in patients with cardiopulmonary disease.
18  in 30 dogs with persistent cyanosis without cardiopulmonary disease.
19 have recognized PM(2.5) as a risk factor for cardiopulmonary diseases.
20 c heart disease, and those free from chronic cardiopulmonary diseases.
21 se is associated with increased mortality in cardiopulmonary diseases.
22  in healthy human heart and in patients with cardiopulmonary diseases.
23  the 18 were initially misdiagnosed as other cardiopulmonary diseases.
24 n the protein is correlated with severity of cardiopulmonary diseases.
25 populations, including those with underlying cardiopulmonary diseases.
26 eased morbidity and mortality in people with cardiopulmonary diseases.
27  impact human health; for example, it causes cardiopulmonary diseases.
28 ent and uncover the developmental origins of cardiopulmonary diseases.
29 ion with pulmonary function tests in various cardiopulmonary diseases.
30 ns in the characterization and management of cardiopulmonary diseases.
31 ent of epigenetic drugs for the treatment of cardiopulmonary diseases.
32 ne healthy sedentary individuals free of any cardiopulmonary disease (42 +/- 12 years, 78 +/- 11 kg),
33                                 Pre-existing cardiopulmonary disease, abnormal troponin, and abnormal
34 els adjusted for age, race, body mass index, cardiopulmonary disease, alcohol use, pacemaker, cholest
35 viduals is associated with increased risk of cardiopulmonary disease and all-cause mortality, but ind
36             Air pollution is associated with cardiopulmonary disease and death in the general populat
37 1-2003 until 2018, we determined the risk of cardiopulmonary disease and death.
38 so that panic anxiety can reflect underlying cardiopulmonary disease and dyspnea can reflect an under
39 ho were > or =65 years old or had underlying cardiopulmonary disease and who were hospitalized with a
40 ffects, including premature mortality due to cardiopulmonary diseases and lung cancer.
41 d donation (including infection, malignancy, cardiopulmonary disease) and uDCD (including hemorrhage,
42 rly adults, high-risk adults with underlying cardiopulmonary disease, and a hospitalized group.
43 me in this cohort of patients with PE and no cardiopulmonary disease, and it may provide a simple sin
44  conditions, including vitamin A deficiency, cardiopulmonary diseases, and hypoxia.
45                          In subjects without cardiopulmonary disease (any heart failure, coronary art
46                     Although prematurity and cardiopulmonary disease are risk factors for severe dise
47 r identify the exact role for iNO therapy in cardiopulmonary diseases associated with hypoxemia or pu
48 e medical system, we identified an increased cardiopulmonary disease burden for residents of Maryland
49 lmonary perfusion, which may be disrupted by cardiopulmonary disease, but this is not well studied, p
50 latory mechanisms, which may be disrupted by cardiopulmonary disease, but this is not well studied, p
51  pulmonary arterial hypertension (IPAH) is a cardiopulmonary disease characterized by cellular prolif
52 lung injury) and increases susceptibility to cardiopulmonary disease (chronic hypoxic pulmonary hyper
53 ed into episodes of care for six conditions: cardiopulmonary disease, coronary and/or cardiac disease
54 dent on whether or not the patient has prior cardiopulmonary disease (CPD).
55  the prognostic performance of age, previous cardiopulmonary disease, D-dimer, brain natriuretic pept
56 raph or history of venous thromboembolism or cardiopulmonary disease does not appear to adversely aff
57  Problems, Tenth Revision (ICD-10) codes for cardiopulmonary diseases extracted from the University o
58 ing a cohort of patients suspected of having cardiopulmonary disease from multiple pathologic causes.
59 lved as a successful treatment for end-stage cardiopulmonary disease in children; however, clear guid
60                 Heartworms can cause serious cardiopulmonary disease in their canid hosts.
61  exclusively associated with prematurity and cardiopulmonary diseases in industrialized countries, pr
62 PDE5) has attracted much interest in several cardiopulmonary diseases, in particular myocardial ische
63               Based on studies on dyspnea in cardiopulmonary diseases, including asthma and asthma-li
64 e detailed characterization of patients with cardiopulmonary diseases is needed, especially with the
65 erial pressure that is not due to coexistent cardiopulmonary disease, known as pulmonary arterial hyp
66                   Associations with specific cardiopulmonary diseases might be useful in exploring po
67 heart surgery (OR, 3.04; 95% CI, 2.26-4.08), cardiopulmonary disease (OR, 1.91; 95% CI, 1.56-2.34), h
68            People with a history of smoking, cardiopulmonary disease, or a body mass index greater th
69 in elderly persons and those with underlying cardiopulmonary disease over a long duration is not well
70 nctional impairment is a frequent finding in cardiopulmonary disease, reflecting both intrinsic atria
71            Although patients with underlying cardiopulmonary disease remain at risk, most complicatio
72 sociated with increased morbidity across the cardiopulmonary disease spectrum.
73   After excluding participants with baseline cardiopulmonary diseases, stroke and cancer, 178,485 men
74  to improve outpatient management of chronic cardiopulmonary diseases such as heart failure.
75         The pathogenesis of life-threatening cardiopulmonary diseases such as pulmonary hypertension
76 as been used to identify patterns typical of cardiopulmonary diseases, such as pulmonary embolism, pn
77 ing patient symptoms and outcomes in various cardiopulmonary diseases, the thorough and accurate asse
78 lmonary embolism (PE) is a potentially fatal cardiopulmonary disease; therefore, rapid risk stratific
79 2 ARI symptoms or exacerbation of underlying cardiopulmonary disease were screened during the 2017-20
80                                              Cardiopulmonary diseases were more common among inpatien
81 d and fifty healthy men, without diabetes or cardiopulmonary disease, were recruited from the communi
82             Hypoxia is often associated with cardiopulmonary diseases, which represent some of the le
83  cognitive deficits, skeletal dysplasia, and cardiopulmonary disease, with death typically occurring